Lenz Therapeutics (LENZ) Q3 2026 earnings review
Lenz eye-drop sales jump 50%, but chief executive steps down
Lenz Therapeutics, the maker of VIZZ prescription eye drops for age-related blurry near vision, grew sales rapidly via online prescribing while slashing its future budget and replacing its chief executive. Third-quarter product revenue jumped 50% from the prior quarter to $2.6 million, with a new telehealth option supplying over half of the prescription gain. Alongside the results, chief executive Eef Schimmelpennink announced his departure and the company unveiled a reorganization to cut projected 2027 operating expenses by over 50%.
| VIZZ net product sales | $2.6M +50% from last quarter |
|---|---|
| Paid prescriptions filled | >38,000 +51% from last quarter |
| Cash and marketable securities | $197.3M -$22.7M from last quarter |
| 2027 operating expense plan | $70–75M cut over 50% from prior projection, excluding stock compensation |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because online consumer pull rescued prescription growth just as an overhaul and a leadership exit exposed the strain of the original launch model. Slashing 2027 cash expenses to $70–75 million slows the cash drain on its $197 million reserve, but even at that reduced rate the business needs several times its current sales to break even.
The question now is whether VIZZ can keep growing at a fast clip once the company cuts its 2027 budget in half under an interim chief executive. Either telehealth and television ads carry patient growth on their own, or the deep cost cuts stall momentum well short of profitability. First-quarter 2027 prescriptions and spending will settle it.
🐂 Bull Case
Telehealth and TV Ads Lifted VIZZ Sales 50%
VIZZ is a once-daily prescription eye drop for age-related blurry near vision, and Lenz Therapeutics launched nationwide television ads and an online prescribing option in July to speed up adoption. "Our strong third-quarter results demonstrate continued progress in the commercialization of VIZZ, with product sales growth of 50%, increasing patient adoption and encouraging refill rates," chief executive Eef Schimmelpennink said.
The July launch offered patients "an integrated online evaluation by independent licensed eye care providers, ePharmacy prescription fulfillment, and home delivery". Net product sales reached $2.6 million on over 38,000 paid prescriptions, up 50% and 51% from the second quarter. By our math, that 51% gain implies roughly 25,200 prescriptions in the prior quarter and about 12,800 added in the third, with telehealth supplying more than half of the increase.
This matters because product revenue had grown only 5% in the second quarter, so letting consumers get a prescription online broke the bottleneck at eye doctors' offices. Still, $2.6 million of quarterly sales covers less than a tenth of the company's current spending. What to watch: fourth-quarter paid prescriptions, because they will show whether online demand keeps growing while the company restructures its commercial team.
Two New Asian Filings Expand International Reach
Alongside its United States launch, the San Diego pharmaceutical group licenses VIZZ to foreign partners in exchange for upfront cash, regulatory milestones, and future royalties. In August and September, regional partner Lotus Pharmaceutical submitted applications for approval in Malaysia and Vietnam, after Middle East partner Lunatus filed in Saudi Arabia in July.
Those submissions brought total regulatory filings outside the United States to eleven, up from nine in the second quarter. The eye-drop maker also recorded $0.8 million in third-quarter license revenue from an upfront payment by Australian partner Arrotex, taking nine-month license revenue to $4.8 million. Because partners fund the overseas launches, future approvals will bring in high-margin cash to help offset domestic marketing costs.
What to watch: the first regulatory approval outside the United States, starting with China or Canada, because an approval triggers milestone cash without adding operating costs.
🐻 Bear Case
Cost Cuts Halve 2027 Spending But Risk Demand
Lenz has been spending more than $30 million a quarter to launch a drug bringing in less than $3 million, prompting a promise of tighter capital discipline that also carried the risk of a commercial cutback. In October, the eye-care company announced a reorganization to "prioritize consumer marketing, allocate capital to maximize sales growth, and reduce operating expenses".
- Third-quarter operating expenses excluding stock compensation: $32.2 million, or $128.8 million annualized by our math
- Targeted 2027 operating expenses excluding stock compensation: $70 million to $75 million, down over 50% from prior internal projections
- Third-quarter net loss: $31.0 million, compared with $2.6 million in net product sales
Cutting projected 2027 cash expenses in half slows the cash drain, which is a positive for the balance sheet, but it proves the initial launch structure — including a field sales force built for 88 to 117 territories — cost far too much for the revenue it produced. Even at the new $18.1 million quarterly spending rate implied by the 2027 plan, VIZZ sales must multiply several times just to break even.
What to watch: first-quarter 2027 selling, general and administrative expenses and prescription volume, because they will show whether halving the budget also slows patient additions.
Chief Executive Steps Down Amid Launch Overhaul
A commercial overhaul just four quarters into a single-product company's launch puts heavy pressure on leadership. Alongside the cost cuts, Schimmelpennink announced he will step down as president and chief executive on December 1, 2026, "to devote more time to other passions" after nearly six years running the company.
Finance chief Dan Chevallard will become interim chief executive while Schimmelpennink stays on as a strategic advisor into 2027. "Our priorities are clear: drive continued increases in consumer awareness, access and adoption of VIZZ and deploy our resources with discipline," Chevallard said. Putting the finance chief in charge fits a phase focused on cutting $5 million of restructuring costs in the fourth quarter, but having no permanent replacement creates uncertainty during a commercial pivot.
What to watch: whether the board names Chevallard permanent chief executive or starts an external search in early 2027, as another leadership change could disrupt the consumer marketing strategy.
Doctor Additions Slowed as Patients Moved Online
Management points to broadening doctor adoption and encouraging refill rates for VIZZ. Since launch, over 15,000 eye care professionals have prescribed the drops, with more than 75% writing multiple prescriptions, and over 60% of online pharmacy patients have bought more than one monthly pack.
However, the numbers underneath those cumulative figures are cooling. Lenz added about 2,000 new prescribing doctors in the third quarter by our math, down from 3,000 added in the second quarter, while the share of repeat prescribers stayed flat at over 75%. In the online pharmacy, the 60% who refill buy at a pace of five packs a year, which means the other 40% buy once and stop — a blended average of 3.4 packs per patient per year by our math.
What to watch: whether the share of online patients buying a second pack rises above 60%, because a flat refill rate forces Lenz to spend heavily on television ads just to replace dropouts.
Risks this quarter didn't answer
Five standing concerns and watch items received no new data in the third-quarter press release, leaving key parts of the commercial story unreadable until the conference call or the quarterly filing.
- Monthly packs sold: the release reported over 38,000 paid prescriptions instead of packs sold (27,000 in the second quarter); the quarterly filing's revenue note will show exact pack volume.
- Second-quarter patient refill rates: the release repeated the five-pack annual rate for fourth-quarter and first-quarter starters without adding the second-quarter group; call commentary will test if newer patients refill as often.
- Retail pharmacy refills: persistence data still covers only the online pharmacy; any disclosure on retail refills would show if walk-in patients stick with the drops.
- Rival eye drops: the release did not mention competing presbyopia treatments Quloci and Uvezy; prescription share data on the call will show if rivals are slowing doctor additions.
- Telehealth eye safety: online prescribing drove over half of new script growth, so post-marketing retinal safety updates in the filing remain essential to watch.
💲 Other KPIs
Cash and marketable securities fell by $22.7 million in the third quarter by our math, a smaller drop than the $38.4 million decline in the second quarter and $34.0 million in the first. Collection of second-quarter license milestones helped slow the drain, leaving a cushion that the 2027 cost cuts aim to stretch.
Reported cost of sales was $0.45 million on $2.60 million of net product revenue, giving an 82.5% gross margin by our math. Excluding $0.35 million of "non-recurring events related to a manufacturing process transition unrelated to product sales", direct product cost was $0.1 million, or a 96.2% direct gross margin.
Diluted share count rose 10.1% from a year ago by our math, reflecting the October 2025 equity sale, and edged up 0.1% from the second quarter. With no new share sales this year, per-share net loss narrowed from $1.02 in the second quarter to $0.99.
🔮 Guidance
Cut. Following its third-quarter review, the company set a 2027 cash operating expense target that reduces projected annual spending by more than 50%. By our math, the $72.5 million middle of the range implies $18.1 million per quarter, down 43.7% from the third quarter's $32.2 million cash operating expense rate.
New. Lenz expects to complete substantially all reorganization activities during the fourth quarter of 2026 and record about $5 million in one-time net restructuring charges. That charge will temporarily lift fourth-quarter cash drain before the lower spending rate takes effect in 2027.
❓ Key Questions
How many monthly VIZZ packs were sold in Q3?
The release reported over 38,000 paid prescriptions (+51% from last quarter) instead of monthly packs sold (27,000 in the second quarter). Because some prescriptions cover three packs at once, investors need the pack count to check true volume and net price per pack.
How much of the sales force is being cut?
Halving projected 2027 operating expenses to $70–75 million while prioritizing television and digital ads suggests deep cuts to the field sales team. Management has not said how many of its planned 117 sales territories remain after the fourth-quarter reorganization.
Why is the chief executive leaving during the commercial pivot?
Eef Schimmelpennink is stepping down on December 1, just one year into the VIZZ launch and in the middle of a restructuring. Shareholders need to know whether the board is searching for a consumer-marketing chief executive or plans to keep finance chief Dan Chevallard.
What is the refill rate for Q2 starters and retail?
Lenz repeated that fourth-quarter and first-quarter online starters buy an average of five packs a year, without giving the rate for second-quarter starters or retail pharmacy patients. Leaving out the newer cohort raises the question of whether later adopters refill less often.